Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015–2016 season in Japan
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Springer New York LLC
Abstract
We report five cases of community- and hospital-acquired infections with oseltamivir- and peramivir-resistant A(H1N1)pdm09 viruses possessing the neuraminidase (NA) H275Y mutation during January–February 2016 in Japan. One case was hospitalized and was receiving oseltamivir for prophylaxis. The remaining four cases were not taking antiviral drugs at the time of sampling. These cases were geographically distant and epidemiologically unrelated. The five viruses showed ~300-fold rise in IC50 values against oseltamivir and peramivir, defined as highly reduced inhibition according to the WHO definition. Overall, the prevalence of the H275Y A(H1N1)pdm09 viruses was 1.8 % (5/282). The resistant viruses possessed the V241I, N369 K, and N386 K substitutions in the NA that have been previously reported among A(H1N1)pdm09 to alter transmission fitness. Analysis of Michaelis constant (Km) revealed that two of the isolates had reduced NA affinity to MUNANA, while the other three isolates displayed a slightly decreased affinity compared to the sensitive viruses. Further studies are needed to monitor the community spread of resistant viruses and to assess their transmissibility. © 2016, The Author(s).
Description
Keywords
Antiviral drug susceptibility, Community transmission, Enzymatic property, Influenza virus a(h1n1)pdm09, Neuraminidase, Oseltamivir resistant, Adolescent, Adult, Aged, Child, Child, preschool, Community-acquired infections, Cross infection, Cyclopentanes, Drug resistance, viral, Female, Genes, viral, Guanidines, Humans, Infant, Influenza a virus, h1n1 subtype, Influenza, human, Japan, Male, Middle aged, Mutation, Oseltamivir, Phylogeny, Seasons, Young adult, Hemagglutinin, Laninamivir, Peramivir, Sialidase, Zanamivir, Cyclopentane derivative, Guanidine derivative, Antiviral resistance, Article, Cancer recurrence, Clinical article, Community acquired infection, Coughing, Disease predisposition, Disease transmission, Drug dose reduction, Fever, Gene sequence, Ha gene, Hospital admission, Hospital discharge, Hospital infection, Human, Human tissue, Ic50, Influenza a (h1n1), Influenza a virus (a/kyoto/15k029/2016(h1n1)), Influenza a virus (a/nagasaki-isahaya/15i007/2016(h1n1)), Influenza a virus (a/nagasaki/15n002/2016(h1n1)), Influenza a virus (a/nagasaki/15n005/2016(h1n1)), Influenza a virus (a/nagasaki/15n011/2016(h1n1)), Influenza a virus (a/nagasaki/15n026/2016(h1n1)), Influenza a virus (a/niigata/15f185/2016(h1n1)), Influenza a virus (a/niigata/15f255/2016(h1n1)), Influenza a virus (a/niigata/15f341/2016(h1n1)), Influenza a virus (a/niigata/15nu001/2016(h1n1)), Influenza a virus (a/perth/261/2009(h1n1)), Influenza a virus (a/perth/265/2009(h1n1)), Influenza a virus (h1n1), Multiple myeloma, Na gene, Nasopharyngeal aspiration, Nonhuman, Preschool child, Rapid influenza antigen detection test, Rapid test, Real time polymerase chain reaction, Seasonal variation, Virus isolation, Virus strain, Drug effects, Genetics, Season, Virology, Virus gene